成人免疫性血小板减少症患者静脉血栓的发生率、特征与管理:多中心前瞻性登记研究CARMEN-France结果
该研究基于法国CARMEN-France前瞻性多中心登记,纳入2013年6月至2022年5月新诊断的1303例成人ITP患者,评估静脉血栓累积发生率(以死亡为竞争风险)并描述事件特征与管理结局。静脉血栓1年累积发生率2.6%(95%CI 1.8-3.7),5年8.6%(95%CI 5.8-12.0);TPO-RA暴露者1年和5年累积发生率分别为9.3%(95%CI 6.2-13.2)和13.4%(95%CI 8.6-19.2)。53例血栓事件中20例(37.7%)为非典型部位,包括5例脑静脉血栓;管理分析提示尽快控制ITP以便早期抗凝(包括使用TPO-RA)是最安全策略。
要点
- 成人ITP患者静脉血栓5年累积发生率为8.6%,TPO-RA暴露者升至13.4%。
- 53例血栓事件中37.7%为非典型部位,包括5例脑静脉血栓。
- 血栓后管理建议尽快控制ITP以利早期抗凝,TPO-RA治疗且持续血栓风险者考虑长期抗凝。
核心结论
- 成人ITP患者静脉血栓累积发生率随时间上升,TPO-RA暴露者风险更高。
- 血栓事件中非典型部位占37.7%,包括脑静脉血栓5例。
- 血栓后尽快控制ITP以利早期抗凝(包括使用TPO-RA)可能是最安全策略。
研究设计与样本
- 观察性研究,基于法国前瞻性多中心国家登记CARMEN-France。
- 纳入2013年6月至2022年5月新诊断的成人ITP患者1303例。
- 以死亡为竞争风险评估静脉血栓累积发生率,并描述事件特征及按管理策略评估结局。
主要发现
- 1303例中53例发生静脉血栓,1年累积发生率2.6%(95%CI 1.8-3.7),5年8.6%(95%CI 5.8-12.0)。
- TPO-RA暴露者暴露1年和5年累积发生率分别为9.3%(95%CI 6.2-13.2)和13.4%(95%CI 8.6-19.2)。
- 发生血栓者年龄更大、静脉血栓史和继发性ITP更常见、ITP更严重、TPO-RA治疗更常见。
- 53例事件中20例(37.7%)为非典型部位,包括5例脑静脉血栓。
- 4例死亡,7例发生大出血。
关键数值与推荐
- 静脉血栓累积发生率:1年2.6%(95%CI 1.8-3.7),5年8.6%(95%CI 5.8-12.0)。
- TPO-RA暴露者累积发生率:暴露1年9.3%(95%CI 6.2-13.2),暴露5年13.4%(95%CI 8.6-19.2)。
- 非典型血栓占53例事件的37.7%,其中脑静脉血栓5例。
临床怎么用
- 对成人ITP患者应评估静脉血栓风险,尤其TPO-RA暴露者。
- 发生血栓后应尽快控制ITP以便早期启动抗凝,可考虑包括TPO-RA在内的策略。
- TPO-RA治疗且存在持续血栓风险因素者应考虑长期抗凝治疗。
局限性
- 为观察性登记研究,管理策略与结局的关联可能受混杂因素影响。
- 原文未报告针对管理策略比较的效应量或统计学检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adult patients with immune thrombocytopenia (ITP) have an increased risk of venous thrombosis as compared to the general population. The management of ITP in the context of anticoagulation is challenging. We conducted an observational study in the prospective, multicenter, national CARMEN-France registry. Adult patients with newly diagnosed ITP between June 2013 and May 2022 were selected. We assessed the cumulative incidence of venous thrombosis during follow-up with death as a competing event, described these events, and assessed patient outcomes depending on management strategies, with a focus on thromboses that occurred during treatment with thrombopoietin receptor agonists (TPO-RA). Among the 1303 patients selected for this study, 53 experienced venous thrombosis. The cumulative incidence of venous thrombosis was 2.6% (95% CI: 1.8-3.7) at 1 year and 8.6% (95% CI: 5.8-12.0) at 5 years. In patients exposed to TPO-RA, the cumulative incidence was 9.3% (95% CI: 6.2-13.2) and 13.4% (95% CI: 8.6-19.2) at 1 and 5 years of exposure, respectively. Patients who experienced thrombosis were older, had more frequently a history of venous thrombosis and secondary ITP, a more severe ITP, and were more frequently treated with TPO-RAs. Twenty (37.7%) of the 53 events were atypical, including five cerebral venous thromboses. Four patients died, and seven experienced major bleeding. The analysis of different managements of ITP after the thrombotic event suggested that the safest strategy was to promptly control ITP to enable early anticoagulation, including using TPO-RAs. Long-term anticoagulation therapy should be considered in patients treated with TPO-RAs and persistent risk factors for thrombosis.
引用
- Therme F, Viallard JF, Rueter M, et al. Incidence, Characteristics, and Management of Venous Thrombosis in Adult Patients With Immune Thrombocytopenia: Results From the Multicenter, Prospective Registry CARMEN-France. Am J Hematol. 2026. PMID: 41504071. doi:10.1002/ajh.70192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。